Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.91 (market cap $772.39M), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.63 (market cap $8.28B). The key difference: Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) is far larger — about 10.7× Ginkgo Bioworks Holdings Inc's market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.85% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 0 Days on average.
| DNA | UGP | |
|---|---|---|
Market Cap | $772.39M | $8.28B |
Volume | 6,453,273 | 3,583,950 |
Sector | Health | Energy |
52-Week High | $15.83 | $7.79 |
52-Week Low | $5.48 | $3.63 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $874.34M | $10.35B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →
